the current short term FDA opportunity is worth circa NZD$25- 27 million in sales (1 million tins) and $5-6 million in profit( less any extra over overheads). Not a game changer by any means.
the big kicker is if FDA grants permanent access and A2 would be able to sell IF ongoing, you could see this growing to 5 million tins a year business i.e NZD$125-150 million sales and $25-30 million in profit.
A2M Price at posting:
$4.69 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)